APA (7th ed.) Citation

K, B., D, T., K, M., M, R., RB, S., C, B., . . . H, C. (2019). Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen. Clinical pharmacology in drug development, 8(4), 541. https://doi.org/10.1002/cpdd.632

Chicago Style (17th ed.) Citation

K, Brown, Thomas D, McKenney K, Reeder M, Simonson RB, Bicer C, Nettles RE, and Crauwels H. "Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen." Clinical Pharmacology in Drug Development 8, no. 4 (2019): 541. https://doi.org/10.1002/cpdd.632.

MLA (9th ed.) Citation

K, Brown, et al. "Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen." Clinical Pharmacology in Drug Development, vol. 8, no. 4, 2019, p. 541, https://doi.org/10.1002/cpdd.632.